Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Camzyos is a prescription cardiac myosin inhibitor containing mavacamten. It is approved for adults with symptomatic New York Heart Association class II or III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. Capsules come in 2.5 mg, 5 mg, 10 mg, and 15 mg strengths. Treatment requires scheduled echocardiograms to monitor heart function.
read more about camzyos ...Mavacamten reversibly inhibits cardiac myosin by binding to myosin and reducing the number of myosin heads available to interact with actin. This decreases excessive actin-myosin cross-bridge formation and reduces excessive heart muscle contraction associated with obstructive hypertrophic cardiomyopathy.
Camzyos is approved for adults with symptomatic New York Heart Association class II or III obstructive hypertrophic cardiomyopathy. Treatment is individualized according to left ventricular ejection fraction, symptoms, and echocardiographic measurements. Starting treatment is not recommended when left ventricular ejection fraction is below 55 percent.
Camzyos is taken once daily, with dose selection based on clinical status and echocardiographic findings. Available strengths are 2.5 mg, 5 mg, 10 mg, and 15 mg. Heart function is assessed before and during treatment. Therapy is interrupted if left ventricular ejection fraction falls below 50 percent or clinical status worsens.
Camzyos carries a boxed warning for heart failure caused by systolic dysfunction. Drug interactions that increase mavacamten exposure can raise this risk, while enzyme inducers can reduce treatment activity. Echocardiographic monitoring is required before and during therapy. Certain CYP2C19 and CYP3A4 inhibitors or inducers are contraindicated with Camzyos.
Camzyos treats symptomatic class II or III obstructive hypertrophic cardiomyopathy in adults.
Camzyos is taken once daily, with dose changes guided by clinical status and echocardiographic findings.
Echocardiograms track left ventricular ejection fraction and help detect systolic dysfunction during treatment.
Yes. The boxed warning covers heart failure caused by systolic dysfunction.
CAMZYOS (mavacamten) Prescribing Information. https://packageinserts.bms.com/pi/pi_camzyos.pdf. Date Accessed September 21, 2026.
DailyMed - CAMZYOS (mavacamten) capsule, gelatin coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=669c936b-3ee6-4e36-8a22-79dd11b1255b. Date Accessed September 21, 2026.
Drug Trials Snapshots: CAMZYOS. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-camzyos. Date Accessed September 21, 2026.
Mavacamten. MedlinePlus. https://medlineplus.gov/druginfo/meds/a622047.html. Date Accessed September 21, 2026.
Mavacamten. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Mavacamten. Date Accessed September 21, 2026.